AN2 Therapeutics Inc Total Liabilities
AN2 Therapeutics Inc total liabilities. Based on the latest financial reports, AN2 Therapeutics Inc (ANTX) has total liabilities worth $5.75 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are AN2 Therapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of AN2 Therapeutics Inc (2019–2025)
Total liabilities of AN2 Therapeutics Inc from 2019 to 2025. This chart illustrates how AN2 Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of AN2 Therapeutics Inc to see how much of total assets are deployed in long-term investments.
AN2 Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of AN2 Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TON Strategy Co
NASDAQ:TONX
|
USA | $5.10 Million |
|
Mieco Chipboard Bhd
KLSE:5001
|
Malaysia | RM268.31 Million |
|
Real Matters Inc
TO:REAL
|
Canada | CA$19.22 Million |
|
Renaissance Global Limited
NSE:RGL
|
India | Rs8.69 Billion |
|
SOHO China Limited
F:45S
|
Germany | €30.88 Billion |
|
Venu Holding Corporation
NYSE MKT:VENU
|
USA | $171.70 Million |
|
Sunjin
KO:136490
|
Korea | ₩911.65 Billion |
|
Jinzhou Port Co Ltd A
SHG:600190
|
China | CN¥9.91 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down AN2 Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ANTX current and non-current assets.
Liquidity & Leverage Metrics
AN2 Therapeutics Inc Total Liabilities Ratios Explained
AN2 Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AN2 Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AN2 Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of AN2 Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.89 Million | -13.17% |
| 2024-12-31 | $10.24 Million | -27.10% |
| 2023-12-31 | $14.04 Million | +95.37% |
| 2022-12-31 | $7.19 Million | +110.92% |
| 2021-12-31 | $3.41 Million | +129.80% |
| 2020-12-31 | $1.48 Million | +67.19% |
| 2019-12-31 | $887.00K | -- |
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15… Read more